Literature DB >> 25683512

IL-17 and insulin/IGF1 enhance adhesion of prostate cancer cells to vascular endothelial cells through CD44-VCAM-1 interaction.

Chong Chen1, Qiuyang Zhang, Sen Liu, Keshab R Parajuli, Yine Qu, Jiandong Mei, Zhiquan Chen, Hui Zhang, Damir B Khismatullin, Zongbing You.   

Abstract

BACKGROUND: Extravasation is a critical step in cancer metastasis, in which adhesion of intravascular cancer cells to the vascular endothelial cells is controlled by cell surface adhesion molecules. The role of interleukin-17 (IL-17), insulin, and insulin-like growth factor 1 (IGF1) in adhesion of prostate cancer cells to the vascular endothelial cells is unknown, which is the subject of the present study.
METHODS: Human umbilical vein endothelial cells (HUVECs) and human prostate cancer cell lines (PC-3, DU-145, LNCaP, and C4-2B) were analyzed for expression of vascular cell adhesion molecule 1 (VCAM-1), integrins, and cluster of differentiation 44 (CD44) using flow cytometry and Western blot analysis. The effects of IL-17, insulin, and IGF1 on VCAM-1 expression and adhesion of prostate cancer cells to HUVECs were examined. The interaction of VCAM-1 and CD44 was assessed using immunoprecipitation assays.
RESULTS: Insulin and IGF1 acted with IL-17 to increase VCAM-1 expression in HUVECs. PC-3, DU-145, LNCaP, and C4-2B cells expressed β1 integrin but not α4 integrin. CD44 was expressed by PC-3 and DU-145 cells but not by LNCaP or C4-2B cells. When HUVECs were treated with IL-17, insulin or IGF1, particularly with a combination of IL-17 and insulin (or IGF1), adhesion of PC-3 and DU-145 cells to HUVECs was significantly increased. In contrast, adhesion of LNCaP and C4-2B cells to HUVECs was not affected by treatment of HUVECs with IL-17 and/or insulin/IGF1. CD44 expressed in PC-3 cells physically bound to VCAM-1 expressed in HUVECs.
CONCLUSIONS: CD44-VCAM-1 interaction mediates the adhesion between prostate cancer cells and HUVECs. IL-17 and insulin/IGF1 enhance adhesion of prostate cancer cells to vascular endothelial cells through increasing VCAM-1 expression in the vascular endothelial cells. These findings suggest that IL-17 may act with insulin/IGF1 to promote prostate cancer metastasis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  IGF1; IL-17; VCAM-1; insulin; prostate cancer metastasis

Mesh:

Substances:

Year:  2015        PMID: 25683512      PMCID: PMC4405436          DOI: 10.1002/pros.22971

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  50 in total

1.  The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α.

Authors:  Shu Zhu; Wen Pan; Xinyang Song; Yan Liu; Xinrui Shao; Yuanjia Tang; Dong Liang; Dongyi He; Honglin Wang; Wenjun Liu; Yufang Shi; John B Harley; Nan Shen; Youcun Qian
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

2.  Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development.

Authors:  Sung Jin Huh; Shile Liang; Arati Sharma; Cheng Dong; Gavin P Robertson
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

3.  IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation.

Authors:  Lucie Roussel; François Houle; Carlos Chan; Yu Yao; Julie Bérubé; Ron Olivenstein; James G Martin; Jacques Huot; Qutayba Hamid; Lorenzo Ferri; Simon Rousseau
Journal:  J Immunol       Date:  2010-03-12       Impact factor: 5.422

Review 4.  CD44 cell adhesion molecules.

Authors:  S Goodison; V Urquidi; D Tarin
Journal:  Mol Pathol       Date:  1999-08

5.  Optimization of formaldehyde cross-linking for protein interaction analysis of non-tagged integrin beta1.

Authors:  Cordula Klockenbusch; Juergen Kast
Journal:  J Biomed Biotechnol       Date:  2010-06-28

Review 6.  Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters.

Authors:  Frank Entschladen; Theodore L Drell; Kerstin Lang; Jan Joseph; Kurt S Zaenker
Journal:  Lancet Oncol       Date:  2004-04       Impact factor: 41.316

7.  Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation.

Authors:  C C Chen; C L Rosenbloom; D C Anderson; A M Manning
Journal:  J Immunol       Date:  1995-10-01       Impact factor: 5.422

8.  CD44 is a major E-selectin ligand on human hematopoietic progenitor cells.

Authors:  C J Dimitroff; J Y Lee; S Rafii; R C Fuhlbrigge; R Sackstein
Journal:  J Cell Biol       Date:  2001-06-11       Impact factor: 10.539

9.  AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1.

Authors:  Chong Chen; Qiuyang Zhang; Sen Liu; Mark Lambrechts; Yine Qu; Zongbing You
Journal:  Front Oncol       Date:  2014-12-01       Impact factor: 6.244

10.  Glycosylated VCAM-1 isoforms revealed in 2D western blots of HUVECs treated with tumoral soluble factors of breast cancer cells.

Authors:  Delina Montes-Sánchez; Jose Luis Ventura; Irma Mitre; Susana Frías; Layla Michán; Aurora Espejel-Nuñez; Felipe Vadillo-Ortega; Alejandro Zentella
Journal:  BMC Chem Biol       Date:  2009-11-22
View more
  16 in total

1.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

Review 2.  Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.

Authors:  Sun H Park; Evan T Keller; Yusuke Shiozawa
Journal:  Calcif Tissue Int       Date:  2017-11-01       Impact factor: 4.333

3.  Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.

Authors:  Joseph Aldahl; Jiaqi Mi; Ariana Pineda; Won Kyung Kim; Adam Olson; Erika Hooker; Yongfeng He; Eun-Jeong Yu; Vien Le; Dong-Hoon Lee; Joseph Geradts; Zijie Sun
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

Review 4.  Evolving cancer-niche interactions and therapeutic targets during bone metastasis.

Authors:  Robert L Satcher; Xiang H-F Zhang
Journal:  Nat Rev Cancer       Date:  2021-10-05       Impact factor: 69.800

5.  IL-17 produced by Th17 cells alleviates the severity of fungal keratitis by suppressing CX43 expression in corneal peripheral vascular endothelial cells.

Authors:  Xiu-Hong Qin; Xiang Ma; Shi-Feng Fang; Zhen-Zhen Zhang; Jian-Min Lu
Journal:  Cell Cycle       Date:  2019-01-20       Impact factor: 4.534

6.  Androgen action in cell fate and communication during prostate development at single-cell resolution.

Authors:  Dong-Hoon Lee; Adam W Olson; Jinhui Wang; Won Kyung Kim; Jiaqi Mi; Hong Zeng; Vien Le; Joseph Aldahl; Alex Hiroto; Xiwei Wu; Zijie Sun
Journal:  Development       Date:  2021-01-11       Impact factor: 6.862

7.  Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis.

Authors:  Ilaha Isali; Mohammed Adel Ali Al-Sadawi; Arshna Qureshi; Ahmad O Khalifa; Mukesh K Agrawal; Sanjeev Shukla
Journal:  Int J Cell Biol Physiol       Date:  2019-10-07

Review 8.  Is there a role for IGF-1 in the development of second primary cancers?

Authors:  Thurkaa Shanmugalingam; Cecilia Bosco; Anne J Ridley; Mieke Van Hemelrijck
Journal:  Cancer Med       Date:  2016-10-13       Impact factor: 4.452

9.  Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.

Authors:  Q Zhang; S Liu; K R Parajuli; W Zhang; K Zhang; Z Mo; J Liu; Z Chen; S Yang; A R Wang; L Myers; Z You
Journal:  Oncogene       Date:  2016-07-04       Impact factor: 9.867

10.  Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

Authors:  Giacomo Canesin; Susan Evans-Axelsson; Rebecka Hellsten; Agnieszka Krzyzanowska; Chandra P Prasad; Anders Bjartell; Tommy Andersson
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.